Advances in Immunology - 1st Edition - ISBN: 9780128047972, 9780128052136

Advances in Immunology, Volume 132

1st Edition

Serial Editors: Frederick Alt
eBook ISBN: 9780128052136
Hardcover ISBN: 9780128047972
Imprint: Academic Press
Published Date: 19th October 2016
Page Count: 188
Sales tax will be calculated at check-out Price includes VAT/GST
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

  • Chapter One: Context- and Tissue-Specific Regulation of Immunity and Tolerance by Regulatory T Cells
    • Abstract
    • 1 Introduction
    • 2 Origins of Treg Cells: “The Third Function of the Thymus (Seddon & Mason, 2000)”
    • 3 Suppressive Properties of Treg Cells
    • 4 Murine Tissue-Specific Treg Cells
    • 5 Human Tissue-Resident Treg Cells
    • 6 Conclusions
  • Chapter Two: Endogenous Retroelements and the Host Innate Immune Sensors
    • Abstract
    • 1 Introduction
    • 2 Toll-Like Receptors
    • 3 RIG-I and MDA5
    • 4 Protein Kinase R
    • 5 Inflammasome
    • 6 Conclusion and Perspectives
  • Chapter Three: B-Lymphopoiesis in Fetal Liver, Guided by Chemokines
    • Abstract
    • 1 Introduction
    • 2 Lineage Choice Between Myeloid and Lymphoid Development
    • 3 Cytokine Receptor Expressions on Early Progenitors in Fetal Liver
    • 4 Changes of Transcription Factor Expressions and of Hematopoietic Differentiation Capacities During Myeloid/Lymphoid Progenitor Development
    • 5 B-Cell Development from Early Fetal Liver Progenitors
    • 6 Nonhematopoietic Mesenchymal Stromal Cells, but not Endothelial Cells, Produce Myeloid-Inducing CSF-1 and Lymphoid-Inducing IL7
    • 7 Selective Chemokines Produced by Endothelium or Mesenchyme Guide Migration of Single Progenitors Expressing Several Chemokine Receptors from Blood to Hepatic Mesenchyme
    • 8 Outlook
    • Acknowledgments
  • Chapter Four: The Roles of the Secreted Phospholipase A2 Gene Family in Immunology
    • Abstract
    • 1 General Aspects of sPLA2s
    • 2 Potential Roles of sPLA2s: Lessons from sPLA2 Transgenic Mice
    • 3 Group IIA sPLA2 (PLA2G2A)
    • 4 Group IID sPLA2 (PLA2G2D)
    • 5 Group IIF sPLA2 (PLA2G2F)
    • 6 Group III sPLA2 (PLA2G3)
    • 7 Group V sPLA2 (PLA2G5)
    • 8 Group X sPLA2 (PLA2G10)
    • 9 Other sPLA2s and sPLA2 Receptor (PLA2R1)
    • 10 Perspectives
    • Acknowledgments
  • Chapter Five: Pleiotropic Roles of Type 1 Interferons in Antiviral Immune Responses
    • Abstract
    • 1 Type 1 Interferon Signaling During Acute Viral Infection
    • 2 Type I Interferon Signaling and Persistent/Chronic Viral Infection
    • 3 Perspective
  • Index
  • Contents of Recent Volumes


Advances in Immunology, a long-established and highly respected publication, presents current developments and comprehensive reviews on immunology. Articles address the wide range of topics that comprise immunology, including molecular and cellular activation mechanisms, phylogeny and molecular evolution, and clinical modalities. Edited and authored by the foremost scientists in the field, each volume provides up-to-date information and directions for the future.

Key Features

  • Contains contributions from leading authorities
  • Informs and updates on all the latest developments in the field of immunology


Immunologists and infectious disease specialists, cell biologists and hematologists


No. of pages:
© Academic Press 2016
Academic Press
eBook ISBN:
Hardcover ISBN:

Ratings and Reviews

About the Serial Editors

Frederick Alt Serial Editor

Frederick Alt received his Ph.D. in Biology from Stanford University in 1977 where he worked with Robert Schimke and discovered gene amplification and genomic instability in mammalian cancer cells. Alt moved to MIT for postdoctoral work with David Baltimore, where he helped elucidate basic principles of recombination in the immune system. His work with Baltimore included the discovery that production of membrane versus secreted immunoglobulin is achieved via differential RNA processing and the discovery that allelic exclusion of Immunoglobulin (Ig) gene rearrangements is controlled by feedback from protein products. With Baltimore, Alt also elucidated major aspects of the V(D)J recombination mechanism, including involvement of site-specific DNA double strand breaks (DSBs) that are end joined, and the discovery of ”N” regions, which represent a major source of antigen receptor diversity.

Dr. Alt moved to Columbia University in 1982 as Assistant Professor of Biochemistry. He became Professor of Biochemistry and Molecular Biophysics in 1985 and HHMI Investigator in 1987. At Columbia, he established the role of Ig chains in regulating B cell development and discovered that antigen receptor genes are assembled by a common V(D)J recombinase. He then elucidated a role for non-coding gene transcription and "chromatin accessibility" as means to target the lineage, stage, and allele specific activity of the V(D)J recombinase. He extended that work to show that IgH class switch recombination (CSR) is B cells to particular IgH classes is directed by activation of non-coding transcription units that contain the CSR target sequences. At Columbia, he also discovered N-myc, based on its amplification in human neuroblastomas and he characterized the Myc cellular oncogene family.

In 1991, Dr. Alt moved to Boston Children' Hospital (BCH) and Harvard Medical School as a Professor of Genetics and HHMI Investigator. He also became a Senior Investigator at the Immune Disease Institute (IDI). He was appointed Charles A. Janeway Professor of Pediatrics in 1993, Scientific Director of IDI in 2005, and Director of the Program in Cellular and Molecular Medicine (PCMM) at Children's Hospital in 2008. He also became President of IDI in 2010 and continues to serve as director since the merger of IDI with BCH where it remains the PCMM. At CHB and IDI, Dr. Alt's group confirmed his earlier proposal with Baltimore that N regions are added by terminal dexoynucleotidyl transferase, demonstrating that TdT is a V(D)J recombinase component. They also discovered that the joining activity of the V(D)J recombinase is carried out by a multi-component general cellular non-homologous DNA end joining (NHEJ) pathway. Subsequently, Dr. Alt was involved in the discovery of a number of the NHEJ factors and he then went on to discover the key role of NHEJ proteins in maintenance of genomic stability. Dr. Alt continues to elucidate many new aspects of the mechanism and control of V(D)J recombination and IgH CSR and also continues to elucidate mechanisms that generate and suppress genomic instability, most recently through development of high through-put methods to study DSBs and chromosomal translocations.

In 1994, Dr. Alt was elected to the U.S. National Academy of Sciences, the American Academy of Arts and Sciences, and the American Academy of Microbiology; in 1999 he was elected to the European Molecular Biology Organization; in 2010 he was elected a Fellow of the American Association for Advancement of Sciences; and in 2011 he was elected to the Institute of Medicine. In 2004, Alt received the Clowes Memorial Award from AACR; in 2005 he received the Rabbi Shai Shacknai Prize from Hebrew University, the Pasarow Foundation Prize for Extraordinary Achievement in Cancer Research, the Leukemia & Lymphoma Society de Villiers International Achievement Award, and the Irvington Institute Award. In 2007, Alt received the NCI Alfred K. Knudson Award for pioneering contributions that have revolutionized Cancer Genetics, the AAI-Huang Meritorious Career Award, and the Novartis Basic Immunology Prize for his discoveries on B cell development and antigen responses. In 2009, he received the Cancer Research Institute William B. Coley Award for Distinguished Research in Basic Immunology for fundamental contributions to understanding of B-cell development and B cell lymphomagenesis. For his overall contributions, he most recently received the 2012 Arthur Kornberg and Paul Berg Award for Lifetime Achievement in Biomedical Sciences from Stanford University Medical School. Dr. Alt serves on numerous editorial boards and is Editor in Chief of Advances in Immunology. He also has served on various national and international advisory boards and is currently Chair, of the SAC of the Cold Spring Harbor Laboratory. Dr. Alt has mentored over 100 students and research fellows, many of whom have become leaders in immunology, genetics, or cancer biology and he received the 2003 American Association of Immunologists Excellence in Mentoring Award. The Cancer Research Institute of New York annually presents the Frederick W. Alt Award for New Discoveries in Immunology.

Affiliations and Expertise

Harvard Medical School, Boston, MA, USA